Loading...
6050

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.SHSE:605016 Stock Report

Market Cap CN¥8.1b
Share Price
CN¥19.20
My Fair Value
CN¥23.08
16.8% undervalued intrinsic discount
1Y33.7%
7D0.7%
Portfolio Value
View

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

SHSE:605016 Stock Report

Market Cap: CN¥8.1b

605016 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shandong Bailong Chuangyuan Bio-Tech
Historical stock prices
Current Share PriceCN¥19.20
52 Week HighCN¥23.68
52 Week LowCN¥11.56
Beta0.51
1 Month Change-6.57%
3 Month Change-7.87%
1 Year Change33.69%
3 Year Change90.95%
5 Year Changen/a
Change since IPO202.13%

Recent News & Updates

Recent updates

Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Solid Profits Have Weak Fundamentals

Nov 06
Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Solid Profits Have Weak Fundamentals

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price

Oct 14
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price

Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)

Sep 29
Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)

Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors

Aug 23
Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors

Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes

Jun 26
Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be

May 06
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be

Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance

May 03
Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance

If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity

Mar 27
If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity

Shareholder Returns

605016CN FoodCN Market
7D0.7%-1.3%3.2%
1Y33.7%6.3%22.8%

Return vs Industry: 605016 exceeded the CN Food industry which returned 8% over the past year.

Return vs Market: 605016 exceeded the CN Market which returned 23% over the past year.

Price Volatility

Is 605016's price volatile compared to industry and market?
605016 volatility
605016 Average Weekly Movement4.7%
Food Industry Average Movement3.7%
Market Average Movement5.4%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.0%

Stable Share Price: 605016 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 605016's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005988Hongjian Zhuowww.sdblcy.com

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. engages in the production and sale of functional sugar in China and internationally. The company offers dietary fibers, including polydextrose and resistant dextrin; prebiotics, such as fructo-oligosaccharide, isomalto- oligosaccharide, galacto- oligosaccharide, and xylo- oligosaccharide.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Fundamentals Summary

How do Shandong Bailong Chuangyuan Bio-Tech's earnings and revenue compare to its market cap?
605016 fundamental statistics
Market capCN¥8.06b
Earnings (TTM)CN¥295.82m
Revenue (TTM)CN¥1.27b
27.3x
P/E Ratio
6.4x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
605016 income statement (TTM)
RevenueCN¥1.27b
Cost of RevenueCN¥797.23m
Gross ProfitCN¥472.26m
Other ExpensesCN¥176.44m
EarningsCN¥295.82m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 30, 2025

Earnings per share (EPS)0.70
Gross Margin37.20%
Net Profit Margin23.30%
Debt/Equity Ratio16.8%

How did 605016 perform over the long term?

See historical performance and comparison

Dividends

0.8%
Current Dividend Yield
25%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/24 09:41
End of Day Share Price 2025/10/24 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cong WangCitic Securities Co., Ltd.
Lin YangGuosen Securities Co., Ltd.
Wei LiuHaitong International Research Limited